tiprankstipranks
Analyst Profile
Followed by 11 other investors
.
Anita Dushyanth

Anita Dushyanth

Berenberg Bank
Wall Street Analyst
Ranked #7,594 out of 8,040 Analysts on TipRanks (#20,403 out of 21,629 overall experts)

Success Rate

35%
11 out of 31 Profitable Transactions

Average Return

-16.60%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Anita Dushyanth's ratings since 2022 and opened each position for the duration of 1 Year:
35.48% of your transactions would have been profitable with an average return of -16.6%

Stock Rating Distribution

33Ratings
100.00% Buy
0.00% Hold
0.00% Sell
Distribution of Anita Dushyanth's ratings

Additional Information

Main Sector:General
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Kodiak Sciences
(KOD)
Rating Type:Buy
Dates:May 14, 2022 - Jan 01, 1970
Gain:105.90%
The most profitable rating made by Anita Dushyanth

Anita Dushyanth's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
Halozyme
Feb 25, 2022
Buy
Reiterated
$56.00
(32.51% Upside)
75%
+11.67%
4
Renalytix AI
Apr 08, 2022
Buy
Reiterated
$31.00
(1078.71% Upside)
0%
-80.08%
4
Sera Prognostics
Apr 27, 2022
Buy
Initiated
$13.00
(504.65% Upside)
0%
-1.70%
1
Urogen Pharma
Apr 27, 2022
Buy
Initiated
$20.00
(143.01% Upside)
100%
+10.50%
1
Insmed
May 07, 2022
Buy
Reiterated
$46.00
(83.05% Upside)
33%
-6.63%
3
Pacira Pharmaceuticals
May 07, 2022
Buy
Reiterated
$88.00
(51.05% Upside)
33%
-1.07%
4
Bioxcel Therapeutics
May 11, 2022
Buy
Reiterated
$69.00
(377.84% Upside)
25%
-24.88%
5
Ocular Therapeutix
May 12, 2022
Buy
Reiterated
$21.00
(301.53% Upside)
50%
+5.10%
2
Kodiak Sciences
May 14, 2022
Buy
Reiterated
$24.00
(129.45% Upside)
40%
-14.52%
5
Ascendis Pharma
May 17, 2022
Buy
Reiterated
$168.00
(81.45% Upside)
25%
-16.68%
4
List of latest recommendations made by Anita Dushyanth. Click to expand and see Anita Dushyanth's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More